Clindamycin treats serious infections caused by susceptible anaerobic bacteria, besides treating infections due to susceptible strains of streptococci, pneumococci, and staphylococci.
The latex-free injection which is expected to be launched in early 2012 will be available in three single-dose vial sizes.
Clindamycin features the company’s PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors.